Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560638 · ClinicalTrials.gov registry record · Phase 2
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT00560638 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 119 participants.
The verdict
NCT00560638, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
Interventions
- DRUG loteprednol etabonate ophthalmic suspension, 0.5%
- DRUG vehicle of loteprednol etabonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00560638
The ClinicalTrials.gov registry entry for NCT00560638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which loteprednol etabonate ophthalmic suspension, 0.5% is the first listed.
NCT00560638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00560638 about?
NCT00560638 is a clinical study titled "Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye". This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabona...
What is the current status of trial NCT00560638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2005-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00560638?
The interventions under investigation include: loteprednol etabonate ophthalmic suspension, 0.5% (DRUG), vehicle of loteprednol etabonate (DRUG).
Who is sponsoring clinical trial NCT00560638?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.